Asia’s biotechnology industry is witnessing rapid transformation, fueled by scientific talent, government funding, and private investment. In 2025, biotech founders are leading breakthroughs in drug discovery, genomics, and medical AI—reshaping healthcare access and treatment innovation across the region. These ten leaders are driving the next chapter of Asia’s biotech revolution.
Image by Zhang Yichi, LinkedIn
Zhang Yichi |
- China
Company: InnoCare Pharma
Market capitalization exceeds $5 billion; listed on HKEX and Nasdaq.
Co-founded in 2015, InnoCare focuses on oncology and autoimmune therapies. CEO Zhang Yichi has led clinical breakthroughs with BTK inhibitors and precision cancer drugs, expanding trials across China, the U.S., and Singapore. Under his leadership, InnoCare has become a symbol of China’s shift from generic pharma to original biopharma innovation.
Image by Business Standard
Kiran Mazumdar-Shaw |
- India
Company: Biocon Limited
Biocon’s market capitalization is approximately $6 billion in 2025.
Founded in 1978, Biocon has grown into one of Asia’s leading biopharmaceutical firms. Founder Kiran Mazumdar-Shaw has been a pioneer in affordable biologics and biosimilars, driving innovation in insulin, oncology, and immunotherapy. Her leadership has placed India at the forefront of cost-effective global biotech solutions.
Image by korea JoongAng Daily
Jeong Woo Han |
- South Korea
Company: Samsung Biologics
Valuation exceeds $50 billion, making it Asia’s largest biotech manufacturer.
Founded in 2011, Samsung Biologics has become a global leader in contract biomanufacturing. CEO Jeong Woo Han oversees the company’s state-of-the-art Songdo facilities, which leverage AI and digital twin systems for scalable production. The firm’s success illustrates how Korea’s tech-industrial ecosystem is redefining global biotech supply chains.
Image by SCMP
Dai Wei |
- China
Company: WuXi AppTec
Market cap around $25 billion in 2025; operates in 30+ countries.
Established in 2000, WuXi AppTec provides integrated R&D and manufacturing solutions for global pharma. CEO Dai Wei leads AI-driven drug discovery programs and data analytics platforms. WuXi’s open-access innovation model has made it a linchpin in Asia’s healthcare research ecosystem.
Image by A*STAR
Lim Chuan Poh |
- Singapore
Company: ClavystBio
Portfolio of 20+ biotech startups across Southeast Asia; part of Temasek’s $500M life sciences fund.
Founded in 2022, ClavystBio focuses on advancing biotech commercialization in Asia. Led by former A*STAR chairman Lim Chuan Poh, it bridges academia and industry by incubating healthtech and biotech ventures. His vision is transforming Singapore into a regional biotech hub with global research collaborations.
Image by Nikkei Asia
Toru Nishikawa |
- Japan
Company: Preferred Networks
Valuation estimated at $2 billion; AI-driven biotech partnerships with Chugai and Toyota.
Founded in 2014, Preferred Networks is best known for industrial AI—but CEO Toru Nishikawa has expanded into biotechnology through drug discovery collaborations. Using deep learning to identify novel compounds, his cross-sector leadership is blurring the lines between AI, pharma, and medical research in Japan.
Image by Morningstar
Michelle Chen |
- Taiwan
Company: TaiGen Biotechnology
Market capitalization of $800 million; several drugs in late-stage clinical trials.
Founded in 2001, TaiGen focuses on anti-infective and oncology therapeutics. CEO Michelle Chen has led successful clinical trials for novel antibiotics addressing global resistance challenges. By emphasizing IP-driven innovation, TaiGen represents Taiwan’s growing presence in advanced drug development.
Image by Pandorum Technologies
Arun Chandru |
- India
Company: Pandorum Technologies
Valuation near $500 million; pioneer in 3D bioprinting and regenerative medicine.
Co-founded in 2011, Pandorum Technologies is redefining tissue engineering with 3D-bioprinted human tissues. CEO Arun Chandru’s focus on organ regeneration for corneal and liver applications has drawn global recognition. His company exemplifies India’s transition from biotech manufacturing to frontier life sciences R&D.
Image by SocialTech Summit 2024
Ryo Kubota |
- Japan
Company: Acucela (subsidiary of Kubota Pharmaceutical Holdings)
Pipeline valued at $1 billion; listed on Tokyo Stock Exchange.
Founded in 2002, Acucela develops ophthalmic therapies for diseases like age-related macular degeneration. CEO Dr. Ryo Kubota has built partnerships across the U.S. and Asia, advancing AI-powered diagnostics for eye health. His work bridges Japanese research excellence with global commercialization.
Image by Cyrus Poonawalla Group
Adar Poonawalla |
- India
Company: Serum Institute of India
Annual production capacity of 1.5 billion vaccine doses; valued at $20 billion+.
Founded in 1966, the Serum Institute is the world’s largest vaccine manufacturer. CEO Adar Poonawalla continues to innovate with AI-driven vaccine development and manufacturing automation. His strategy ensures that India remains a global epicenter for affordable immunization and biotech research.
From Singapore’s biotech incubators to India’s vaccine giants and China’s AI-driven pharma platforms, Asia’s biotech leaders are proving that scientific innovation and entrepreneurship go hand in hand. Their breakthroughs are not only advancing healthcare outcomes but also establishing Asia as the next global biotechnology frontier.
Discover more inspiring journeys on Feature.Asia: 10 Entrepreneurs Under 30 Changing Asia’s Economy
